Taysha Gene Therapies Stock (NASDAQ: TSHA)

Taysha Gene Therapies

TAYSHA GENE THERAPIES INC

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Driving Down Costs

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

COOP

CORT

NIVF

PCVX

SSBK

TSHA

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet

Nvidia, Palantir, Clover Health, Joby Aviation, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Movers

ACIU

JBLU

OSCR

SPIR

WYNN

Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday

xr:d:DAFkdW1Tf7Y:2,j:2276961543181188932,t:23053105

Pre-Market Outlook

HROW

IBTA

SMCI

TTEK

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies Inc

Press Releases

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Financing

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Absci

Abivax

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Altimmune

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Celcuity

Erasca

Heron Therapeutics

Keros Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Relay Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sana Biotechnology

Stoke Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tourmaline Bio

Upstream Bio

Verve Therapeutics

Needham

Chardan Capital

Canaccord Genuity

Cantor Fitzgerald

JMP Securities

Comments

Taysha Gene Therapies

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga